Iterum therapeutics plc (ITRM)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-103,130

-77,056

-29,406

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

152

136

65

Share-based compensation expense

2,173

1,290

392

Gain on short-term investments

125

423

-

Non-cash gain on short-term investments

-

278

-44

Interest on short-term investments

5

40

95

Amortization of debt discount and deferred financing costs

362

360

-

Issuance of ordinary shares under subscription agreement

3,037

1,362

-

Other

-752

-362

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-2,471

3,613

3,815

Other assets

1,166

2,273

782

Accounts payable

11,446

849

1,671

Accrued expenses

5,851

3,072

1,236

Income taxes

123

120

6

Other liabilities

-826

242

80

Net cash used in operating activities

-78,885

-75,890

-30,604

Cash flows from investing activities:
Purchases of property and equipment

24

90

812

Purchases of short-term investments

-

96,493

53,275

Proceeds from sale of short-term investments

40,125

87,925

22,500

Net cash provided by investing activities

40,101

-8,658

-31,587

Cash flows from financing activities:
Proceeds from issuance of debt, net of debt issuance costs

-

14,507

-

Repayments of long-term debt

1,034

-

-

Proceeds from issuance of ordinary shares on initial public offering, net of issuance costs

-

74,153

-

Proceeds from exercise of share options

60

7

-

Net cash provided by financing activities

-974

120,842

45,867

Effect of exchange rates on cash and cash equivalents

-22

-108

-

Net increase in cash, cash equivalents and restricted cash

-39,780

36,186

-16,324

Supplemental Disclosure of Cash Flow Information:
Income tax paid—U.S.

414

352

439

Interest paid

1,399

809

-

Series B Convertible Preferred Shares
Proceeds from issuance of convertible preferred shares

-

32,175

45,867